WELLESLEY, Mass.--(BUSINESS WIRE)--Point Therapeutics, Inc. (NASDAQ: POTP) announced today that the Company received an additional notice of non-compliance on November 13, 2007 from the staff of the Listing Qualifications Department of The NASDAQ Stock Market (the “Staff”). Based upon a review of the Company’s Form 10-Q for the quarter ended September 30, 2007, the Staff determined that the Company no longer satisfies the NASDAQ stockholders’ equity requirement for continued listing of $2.5 million, as set forth in Marketplace Rule 4310(c)(3). The Company has been afforded the opportunity to present its views with respect to this additional deficiency to the NASDAQ Listing Qualifications Panel (the “Listing Panel”).
